OBJECTIVE ASSESSMENT - EXAM
NSG552 / NSG 552 Exam 2
Psychopharmacology
Grade A Questions and Verified Answers | 100% Correct
Wilkes 2026/2027
QUESTIONS VERIFIED ANSWERS PASSING SCORE EDITION
75 100% 80% 2026/2027
TOPICS COVERED
* Neurobiology & Receptor Pharmacology * Ketamine
Clozapine &REMS
Emerging
& Agranulocytosis
Therapies
* CYP450 Metabolism & Drug Interactions * ADHD: Stimulants & Non-Stimulants
* Pharmacokinetics & Steady-State Kinetics * Substance Use: Opioid, Alcohol, Tobacco
* SSRIs, SNRIs, TCAs & MAOIs * Serotonin Syndrome & NMS
* Atypical Antipsychotics & D2 Partial Agonism * Geriatric & Pregnancy Considerations
* Mood Stabilizers: Lithium, Valproate, Lamotrigine * Tardive Dyskinesia & EPS Management
* Benzodiazepines, Z-Drugs & Buspirone * Metabolic Monitoring & Diabetes Risk
COVER PAGE - 1
, SECTION 1: NEUROBIOLOGY, PHARMACOKINETICS & PHARMACODYNAMICS
Q1 NSG552 / NSG 552 Exam 2 (Latest 2026/2027): P...
Q1. A 34-year-old patient newly prescribed sertraline asks why the initial dose must be low and titrated
slowly over several weeks. The nurse explains that this approach primarily accounts for which
pharmacokinetic phenomenon?
A. First-pass hepatic metabolism reducing initial bioavailability
B. Auto-inhibition of CYP2D6 leading to nonlinear accumulation
C. Receptor desensitization requiring time for therapeutic adaptation
D. Achieving steady-state plasma concentration proportional to the half-life
Correct Answer: D
Rationale: Sertraline has a half-life of approximately 26 hours, and steady-state concentrations are reached in about 5-7 days.
Slow titration allows plasma levels to stabilize and minimizes early adverse effects like gastrointestinal distress or activation
syndrome. First-pass metabolism is not the primary reason for slow titration, and sertraline is a weak CYP2D6 inhibitor rather
than an auto-inhibitor.
NSG552 / NSG 552 Exam 2 (Latest 2026/2027): Psychopharmacology | Grade A Questions and Verified Answers | 100% Correct - Wilkes 2026/2027 | Page 2
, Q2 NSG552 / NSG 552 Exam 2 (Latest 2026/2027): P...
Q2. A psychiatric nurse practitioner is reviewing cytochrome P450 interactions before adding aripiprazole
to a patient's regimen that includes fluoxetine and omeprazole. Which metabolic pathway requires the
most careful monitoring in this polypharmacy scenario?
A. CYP1A2 induction by aripiprazole causing subtherapeutic levels of concurrent agents
B. CYP2D6 inhibition by fluoxetine increasing aripiprazole plasma concentrations
C. CYP3A4 inhibition by omeprazole reducing the clearance of both antipsychotics
D. CYP2C19 polymorphism causing unpredictable metabolism of all three medications
Correct Answer: B
Rationale: Fluoxetine is a potent CYP2D6 inhibitor, and aripiprazole is primarily metabolized by CYP2D6 and CYP3A4.
Inhibiting CYP2D6 can increase aripiprazole levels by 2-fold, necessitating dose reduction. Omeprazole inhibits CYP2C19, not
CYP3A4, and while CYP2C19 polymorphisms matter for some drugs, they are less relevant for this specific combination.
Q3 NSG552 / NSG 552 Exam 2 (Latest 2026/2027): P...
Q3. During a medication education session, a patient asks why clozapine requires weekly blood draws for
the first six months. The nurse correctly identifies which pharmacodynamic risk as the primary rationale
for this monitoring protocol?
A. Dose-dependent hepatotoxicity requiring liver enzyme surveillance
B. Idiosyncratic agranulocytosis mediated by immune-mediated neutrophil destruction
C. Cumulative cardiotoxicity from catecholamine surge and myocardial inflammation
D. Progressive renal dysfunction secondary to anticholinergic urinary retention
Correct Answer: B
Rationale: Clozapine carries a black-box warning for agranulocytosis, an idiosyncratic immune-mediated reaction causing
severe neutropenia. The REMS program mandates ANC monitoring weekly for 6 months, then biweekly. While myocarditis
and cardiomyopathy are also risks, they do not drive the specific 6-month weekly blood draw protocol.
NSG552 / NSG 552 Exam 2 (Latest 2026/2027): Psychopharmacology | Grade A Questions and Verified Answers | 100% Correct - Wilkes 2026/2027 | Page 3
, Q4 NSG552 / NSG 552 Exam 2 (Latest 2026/2027): P...
Q4. A 29-year-old patient with treatment-resistant depression is started on a monoamine oxidase
inhibitor. The nurse provides dietary counseling emphasizing tyramine restriction. Which neurochemical
mechanism explains why tyramine ingestion poses a life-threatening risk with this drug class?
A. Tyramine displaces norepinephrine from synaptic vesicles, causing massive catecholamine release when
MAO is inhibited
B. Tyramine acts as a direct serotonin receptor agonist, precipitating serotonin syndrome in combination with
MAOIs
C. Tyramine inhibits presynaptic reuptake of dopamine, leading to hypertensive crisis through D1 receptor
overstimulation
D. Tyramine is metabolized by MAO-B into a toxic metabolite that directly damages vascular endothelium
Correct Answer: A
Rationale: Tyramine is an indirect sympathomimetic that normally undergoes first-pass metabolism by intestinal and hepatic
MAO-A. When MAO is inhibited, dietary tyramine enters the systemic circulation and displaces norepinephrine from storage
vesicles, causing a sudden hypertensive crisis. It does not act as a serotonin agonist or produce a toxic metabolite.
Q5 NSG552 / NSG 552 Exam 2 (Latest 2026/2027): P...
Q5. A nurse is caring for a patient who accidentally took a double dose of lithium carbonate. When
assessing for early signs of lithium toxicity, which physiologic parameter reflects the drug's narrow
therapeutic index and zero-order elimination kinetics at toxic levels?
A. Progressive confusion and ataxia developing after a single supratherapeutic dose
B. Rapid normalization of serum levels within 12 hours due to first-order renal clearance
C. Delayed onset of tremor and gastrointestinal distress proportional to the glomerular filtration rate
D. Accumulation in renal tubules causing polyuria and nephrogenic diabetes insipidus within hours
Correct Answer: A
Rationale: Lithium has a narrow therapeutic window of 0.6-1.2 mEq/L and follows first-order kinetics at therapeutic doses but
can approach zero-order at toxic levels. Early signs include confusion, ataxia, coarse tremor, and GI distress. While
nephrogenic diabetes insipidus is a chronic lithium effect, it does not develop within hours of a single overdose.
NSG552 / NSG 552 Exam 2 (Latest 2026/2027): Psychopharmacology | Grade A Questions and Verified Answers | 100% Correct - Wilkes 2026/2027 | Page 4